Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma

Abstract The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in multiple clinical trials. The second-ge...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jing Zhang (Author), Xueying Lu (Author), Jianyong Li (Author), Yi Miao (Author)
Formato: Livro
Publicado em: BMC, 2022-04-01T00:00:00Z.
Assuntos:
Acesso em linha:Connect to this object online.
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

Connect to this object online.

3rd Floor Main Library

Detalhes do Exemplar 3rd Floor Main Library
Área/Cota: A1234.567
Cód. Barras: 1 Disponível